Biomedicines (Jan 2022)

The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy

  • Siarhei A. Dabravolski,
  • Vasily N. Sukhorukov,
  • Vladislav A. Kalmykov,
  • Andrey V. Grechko,
  • Nikolay K. Shakhpazyan,
  • Alexander N. Orekhov

DOI
https://doi.org/10.3390/biomedicines10020254
Journal volume & issue
Vol. 10, no. 2
p. 254

Abstract

Read online

Kruppel like factor 2 (KLF2) is a mechanosensitive transcription factor participating in the regulation of vascular endothelial cells metabolism. Activating KLF2 in endothelial cells induces eNOS (endothelial nitric oxide synthase) expression, subsequent NO (nitric oxide) release, and vasodilatory effect. In addition, many KLF2-regulated genes participate in the anti-thrombotic, antioxidant, and anti-inflammatory activities, thereby preventing atherosclerosis development and progression. In this review, we summarise recent evidence suggesting that KLF2 plays a major role in regulating atheroprotective effects in endothelial cells. We also discuss several recently identified repurposed drugs and natural plant-based bioactive compounds with KLF2-mediated atheroprotective activities. Herein, we present a comprehensive overview of the role of KLF2 in atherosclerosis and as a pharmacological target for different drugs and natural compounds and highlight the potential application of these phytochemicals for the treatment of atherosclerosis.

Keywords